Aristea Therapeutics Overview
- Year Founded
-
2018
- Status
-
Out of Business
- Employees
-
10
- Latest Deal Type
-
Out of Business
Aristea Therapeutics General Information
Description
Operator of a drug development company intended to treat serious inflammatory diseases. The company develops new medicines through a focused, diligent and agile approach, enabling patients to have access to a pipeline of drugs focused on palmoplantar pustulosis, hidradenitis suppurtiva, IBD, familial mediaterranean fever, and behcet's disease.
Contact Information
Website
www.aristeatx.comCorporate Office
- 12770 High Bluff Drive
- Suite 380
- San Diego, CA 92130
- United States
Corporate Office
- 12770 High Bluff Drive
- Suite 380
- San Diego, CA 92130
- United States
Aristea Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 10-Feb-2023 | Completed | Out of Business | |||
| 3. Merger/Acquisition | 27-Jul-2021 | Cancelled | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series B) | 27-Jul-2021 | $63M | $78M | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC (Series A) | 13-Aug-2018 | $15M | $15M | Completed | Clinical Trials - Phase 2 |
Aristea Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A2 | ||||||||
| Series A1 | 3,063,025 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 9.38% |
Aristea Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aristea Therapeutics Patents
Aristea Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4161499-A1 | Use of a combination of colchicine and a cxcr-2 inhibitor for the treatment or prevention of familial mediterranean fever (fmf) and flare-ups thereof | Inactive | 05-Jun-2020 | ||
| US-20230210792-A1 | Use of a combination of colchicine and a cxcr-2 inhibitors for the treatment or prevention of familial mediterranean fever (fmf) and flare-ups thereof | Pending | 05-Jun-2020 |
Aristea Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aristea Therapeutics FAQs
-
When was Aristea Therapeutics founded?
Aristea Therapeutics was founded in 2018.
-
Where is Aristea Therapeutics headquartered?
Aristea Therapeutics is headquartered in San Diego, CA.
-
What is the size of Aristea Therapeutics?
Aristea Therapeutics has 10 total employees.
-
What industry is Aristea Therapeutics in?
Aristea Therapeutics’s primary industry is Drug Discovery.
-
Is Aristea Therapeutics a private or public company?
Aristea Therapeutics is a Private company.
-
What is Aristea Therapeutics’s current revenue?
The current revenue for Aristea Therapeutics is .
-
How much funding has Aristea Therapeutics raised over time?
Aristea Therapeutics has raised $78M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
